Drug intelligence / Profile preview

QHL-625

Development stage: Preclinical
Lead developer: Affinity Biopharmaceutical
Modality: Prodrugs/Conditional Activator Small Molecules → Small Molecules

Overview

QHL-625 is an investigational small molecule drug conjugate (SMDC) developed by Affinity Biopharmaceutical, targeting Cyclin-dependent kinase 4 (CDK4) and Cyclin-dependent kinase 6 (CDK6). Utilizing Affinity's proprietary SMDC platform, QHL-625 is designed to deliver a potent CDK4/6 inhibitor payload directly to tumor tissues. This targeted approach aims to enhance the therapeutic index by concentrating the cell-cycle inhibitory effect within the tumor microenvironment while reducing systemic exposure and associated toxicities. It is currently being evaluated in preclinical studies for the treatment of various solid tumors.

Targets

CDK6 (Cyclin-dependent kinase 6)CDK4 (Cyclin-dependent kinase 4)

Beyond the preview

Go deeper on QHL-625.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QHL-625.

Explore the full profile